| Project/Area Number |
26670644
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Date Isao 岡山大学, 医歯薬学総合研究科, 教授 (70236785)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
黒住 和彦 岡山大学, 大学病院, 講師 (20509608)
杉生 憲志 岡山大学, 大学病院, 准教授 (40325105)
安原 隆雄 岡山大学, 医歯薬学総合研究科, 講師 (50457214)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | Bevacizumab / Integrin / Molecular targeted drug / invasion / glioma |
|---|
| Outline of Final Research Achievements |
Glioblastoma is known to secrete high levels of vascular endothelial growth factor (VEGF). Clinical studies with bevacizumab, a monoclonal antibody to VEGF, have demonstrated convincing therapeutic benefits in glioblastoma patients. However, its induction of invasive proliferation has also been reported. We examined the effects of treatment with cilengitide, an integrin inhibitor, on bevacizumab-induced invasive changes in glioma. U87ΔEGFR cells were stereotactically injected into the brain of nude mice or rats. When the rats were treated with a combination of bevacizumab and cilengitide, the depth of tumor invasion was significantly less than with only bevacizumab. Pathway analysis demonstrated the inhibition of invasion associated genes such as the integrin-mediated cell adhesion pathway in the combination group. This study showed that the combination of bevacizumab with cilengitide exerted its anti-invasive effect.
|
